Broadcast Date: 
  • Time: 

The COVID-19 health crisis has exposed some shortcomings in the global response to infectious disease prevention and management. How rapidly we respond to disease outbreaks with diagnostic and therapeutic measures could help to save thousands of lives. In recent years, mRNA vaccines have been developed as a platform technology with the potential to be used for a broad range of targets—with self-amplifying mRNA vaccines representing some of the most potent examples of this new platform technology. Their synthetic production methods, combined with the modern tools of bioinformatics and synthetic biology, enable these vaccines to be produced rapidly from an electronic gene sequence. Additionally, non-viral delivery of these novel mRNA vaccines means that issues of anti-vector immunity are avoided, and potent immune responses are elicited at low doses of the nucleic acid.

In this webinar, we will hear about data innovations from seven years of research at Novartis Vaccines on self-amplifying mRNA technology and how this approach could enable the concept of vaccines on-demand as a rapid response to a real threat rather than the deployment of strategic stockpiles based on epidemiological predictions of a possible threat.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

Produced with support from:

TriLink Bio logo
Andy Geal
Andy Geall, PhD
Chief Executive Officer
RNA Consulting
Anton McCaffrey